Researchers who examined PET, cerebrospinal fluid and cognitive testing data from 445 cognitively healthy adults with an average age of 74 found that 32.2% of those with elevated brain amyloid levels at baseline had symptoms associated with early-stage Alzheimer's disease at four years and 88.2% had developed symptoms at 10 years. Although no effective preclinical interventions are available, the findings in the Journal of the American Medical Association could be applied to educate and help families plan for future illness, researchers said.
Preclinical brain amyloid elevation could signal future cognitive decline
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.